PFG Investments LLC Sells 43,987 Shares of ADMA Biologics, Inc. (NASDAQ:ADMA)

PFG Investments LLC reduced its stake in ADMA Biologics, Inc. (NASDAQ:ADMA) by 16.6% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 221,153 shares of the biotechnology company’s stock after selling 43,987 shares during the period. PFG Investments LLC owned approximately 0.10% of ADMA Biologics worth $4,421,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in the stock. Quest Partners LLC bought a new position in ADMA Biologics in the 2nd quarter valued at $29,000. EntryPoint Capital LLC purchased a new stake in shares of ADMA Biologics in the 1st quarter valued at about $31,000. USA Financial Formulas boosted its position in shares of ADMA Biologics by 8.6% during the 3rd quarter. USA Financial Formulas now owns 6,817 shares of the biotechnology company’s stock valued at $136,000 after acquiring an additional 539 shares during the last quarter. CWM LLC grew its holdings in shares of ADMA Biologics by 114.2% during the second quarter. CWM LLC now owns 8,192 shares of the biotechnology company’s stock worth $92,000 after purchasing an additional 4,367 shares in the last quarter. Finally, Acadian Asset Management LLC bought a new position in shares of ADMA Biologics in the second quarter worth approximately $93,000. 75.68% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at ADMA Biologics

In other news, Director Lawrence P. Guiheen sold 9,000 shares of the company’s stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $18.47, for a total value of $166,230.00. Following the transaction, the director now owns 153,941 shares in the company, valued at approximately $2,843,290.27. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. In other ADMA Biologics news, Director Lawrence P. Guiheen sold 9,000 shares of the business’s stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $18.47, for a total value of $166,230.00. Following the completion of the transaction, the director now owns 153,941 shares of the company’s stock, valued at approximately $2,843,290.27. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Adam S. Grossman sold 236,889 shares of the firm’s stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $17.69, for a total transaction of $4,190,566.41. Following the sale, the chief executive officer now directly owns 2,059,726 shares in the company, valued at approximately $36,436,552.94. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 466,900 shares of company stock valued at $8,224,121 in the last quarter. 3.70% of the stock is owned by insiders.

ADMA Biologics Trading Down 0.9 %

Shares of NASDAQ ADMA traded down $0.15 during midday trading on Friday, hitting $15.81. 2,730,268 shares of the company traded hands, compared to its average volume of 3,616,037. The company has a debt-to-equity ratio of 0.74, a quick ratio of 2.80 and a current ratio of 6.87. ADMA Biologics, Inc. has a 12-month low of $3.16 and a 12-month high of $21.13. The stock has a 50-day moving average price of $17.93 and a 200 day moving average price of $12.98. The firm has a market cap of $3.66 billion, a P/E ratio of -790.50 and a beta of 0.62.

ADMA Biologics (NASDAQ:ADMA) last issued its quarterly earnings results on Thursday, August 8th. The biotechnology company reported $0.13 earnings per share for the quarter, topping the consensus estimate of $0.08 by $0.05. The company had revenue of $107.20 million for the quarter, compared to analysts’ expectations of $86.44 million. ADMA Biologics had a return on equity of 38.79% and a net margin of 10.53%. The firm’s revenue for the quarter was up 78.4% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.02) earnings per share. As a group, analysts expect that ADMA Biologics, Inc. will post 0.49 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on ADMA shares. HC Wainwright restated a “buy” rating and set a $18.00 price target on shares of ADMA Biologics in a research report on Monday, October 14th. Cantor Fitzgerald restated an “overweight” rating and issued a $20.00 target price on shares of ADMA Biologics in a research report on Friday, September 20th. One investment analyst has rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $15.50.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.